Clinical Trials Browser

Adenocarcinoma × Gastrointestinal × 90 days × Clear all

NCT06205836 2026-03-17

Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma, Carcinoma, Colorectal Neoplasms

NCT07455422 2026-03-06

Endeavor-2

Phase NA Not yet recruiting

Gastrointestinal

Adenocarcinoma, Barrett Esophagus

NCT05672524 2026-03-04

A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma, Rectal Neoplasms

NCT05063565 2026-03-02

ROWAN

Phase 2 Active not recruiting

Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

NCT04605913 2026-02-25

Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC

Phase 1/2 Recruiting

Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

NCT05014776 2026-02-24

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

17 enrolled 8 charts

Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Neoplasms

NCT07124000 2026-02-24

DP-04

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Adenocarcinoma, Anus Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Melanoma, Mouth Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Testicular Neoplasms, Thyroid Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma

NCT07431281 2026-02-24

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Phase 3 Recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT04379596 2026-02-23

DG-03

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT07259317 2026-02-20

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Ductal

NCT05922930 2026-02-19

Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer

Phase 1/2 Recruiting

GastrointestinalGynecologic

Adenocarcinoma, Ovarian Neoplasms, Pancreatic Neoplasms

NCT03504397 2026-02-13

Spotlight

Phase 3 Active not recruiting

565 enrolled 63 charts 1 FDA

Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT03653507 2026-02-06

GLOW

Phase 3 Active not recruiting

507 enrolled 65 charts 1 FDA

Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT03323944 2026-01-30

CAR T Cell Immunotherapy for Pancreatic Cancer

Phase 1 Terminated

Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

NCT05620628 2026-01-21

Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT07284186 2026-01-16

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

GastrointestinalThoracic

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04704934 2026-01-12

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Phase 3 Active not recruiting

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms